Tango Therapeutics Reports 82% Tumor Response Rate for Vopimetostat Combination in Advanced Pancreatic Cancer at ESMO 2026

STAT News reported on October 23, 2026 that Tango Therapeutics presented ESMO 2026 trial results for vopimetostat in combination therapy for advanced pancreatic cancer, with an 82% tumor response rate. Details beyond the reported headline figure were not verified from the source.